1. Inicio
  2. Publicaciones
  3. AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial

AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Martinelli G.
  • Santoro A.
  • Gambacorti-Passerini C.
  • Polo S.V.
  • Solomon S.R.
  • Mukherjee S.
  • Lech-Maranda E.
  • Levy M.Y.
  • Wierzbowska A.
  • Calbacho-Robles M.
  • Marconi G.
  • Giannini M.B.
  • Angelosanto N.
  • Mughal T.I.
  • Galleu A.
  • Blotta S.
  • Ravandi F.

Grupos

Abstract

Abstract no disponible

Datos de la publicación

ISSN/ISSNe:
2152-2650, 2152-2669

Clinical Lymphoma Myeloma & Leukemia  CIG MEDIA GROUP, LP

Tipo:
Article
Páginas:
243-244
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,778 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Keywords

  • Flt3 ligand; protein kinase Pim 1; protein tyrosine kinase; protein tyrosine kinase inhibitor; sel 24men 1703; unclassified drug; acute myeloid leukemia; adult; antineoplastic activity; Article; asthenia; blood cell count; cancer patient; cancer recurrence; cancer resistance; clinical article; cohort analysis; drug dose escalation; drug safety; gene mutation; hematopoietic stem cell; human; human cell; leukemia remission; monotherapy; multicenter study; multiple cycle treatment; open study; outcome assessment; overall response rate; phase 1 clinical trial; phase 2 clinical trial; pneumonia; preliminary data; recommended drug dose; remission; transplantation

Campos de Estudio

Cita

Compartir